HSA
CERO

HBK Sorce Advisory’s CERo Therapeutics CERO Stock Holding History

HBK Sorce Advisory’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13
Closed -$1.57K – 626
2024
Q4 		$1.57K Buy
+13
New +$3.03K ﹤0.01% 579

Other funds holding CERO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
APP
Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

HBK Sorce Advisory's CERO Position: Q1 2025 in Review

HBK Sorce Advisory sold out of CERo Therapeutics (CERO) in Q1 2025, closing a stake of 13 shares — an estimated $1.57K sold.

HBK Sorce Advisory first reported a position in CERO in Q4 2024 and held it in 1 quarter. The position peaked at $1.57K in Q4 2024. 13 funds tracked by Wall St. Rank hold CERO as of Q1 2025.

  • HBK Sorce Advisory reported no remaining CERo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HBK Sorce Advisory sold 13 CERo Therapeutics shares in Q1 2025, an estimated $1.57K.
  • HBK Sorce Advisory first reported a position in CERo Therapeutics in Q4 2024 and held it in 1 quarter.
  • HBK Sorce Advisory's CERo Therapeutics position peaked at $1.57K in Q4 2024.
  • 13 funds tracked by Wall St. Rank held CERo Therapeutics as of Q1 2025.

Based on HBK Sorce Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.